Provectus Biopharmaceuticals Stock Price, News & Analysis (OTCMKTS:PVCT)

$0.08 0.00 (0.00 %)
(As of 01/19/2018 04:00 PM ET)
Previous Close$0.08
Today's Range$0.08 - $0.08
52-Week Range$0.02 - $0.09
Volume412,190 shs
Average Volume1.30 million shs
Market Capitalization$29.51 million
P/E Ratio-0.98
Dividend YieldN/A

About Provectus Biopharmaceuticals (OTCMKTS:PVCT)

Provectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

Receive PVCT News and Ratings via Email

Sign-up to receive the latest news and ratings for PVCT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major


Debt-to-Equity Ratio-0.97%
Current Ratio0.13%
Quick Ratio0.13%


Trailing P/E Ratio-0.9775
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book7.82


Trailing EPS($0.08)
Net Income$-24,420,000.00
Net MarginsN/A
Return on Equity-2,045.29%
Return on Assets-334.46%


Outstanding Shares370,740,000

Provectus Biopharmaceuticals (OTCMKTS:PVCT) Frequently Asked Questions

What is Provectus Biopharmaceuticals' stock symbol?

Provectus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "PVCT."

Who are some of Provectus Biopharmaceuticals' key competitors?

Who are Provectus Biopharmaceuticals' key executives?

Provectus Biopharmaceuticals' management team includes the folowing people:

  • Dominic Rodrigues, Chairman of the Board
  • Timothy C. Scott Ph.D., President (Age 51)
  • John R. Glass CPA, Interim Chief Financial Officer (Age 72)
  • Eric A. Wachter Ph.D., Chief Technology Officer, Director (Age 52)
  • Bruce Horowitz, Director
  • Jan E Koe, Independent Director (Age 65)

How do I buy Provectus Biopharmaceuticals stock?

Shares of Provectus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Provectus Biopharmaceuticals' stock price today?

One share of Provectus Biopharmaceuticals stock can currently be purchased for approximately $0.08.

How big of a company is Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals has a market capitalization of $29.51 million. The company earns $-24,420,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis. Provectus Biopharmaceuticals employs 2 workers across the globe.

How can I contact Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals' mailing address is 10025 INVESTMENT DRIVE SUITE 250, KNOXVILLE TN, 37932. The company can be reached via phone at 865-769-4011 or via email at [email protected]

MarketBeat Community Rating for Provectus Biopharmaceuticals (PVCT)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  5 (Vote Outperform)
Underperform Votes:  4 (Vote Underperform)
Total Votes:  9
MarketBeat's community ratings are surveys of what our community members think about Provectus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Provectus Biopharmaceuticals (OTCMKTS:PVCT) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Provectus Biopharmaceuticals (OTCMKTS:PVCT) Earnings History and Estimates Chart

Earnings by Quarter for Provectus Biopharmaceuticals (OTCMKTS:PVCT)

Provectus Biopharmaceuticals (OTCMKTS PVCT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017($0.01)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.01)ViewN/AView Earnings Details
3/31/2017Q4 2016($0.02)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.04)ViewN/AView Earnings Details
8/9/2016Q2 2016($0.02)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.04)ViewN/AView Earnings Details
3/30/2016Q4 2015($0.05)ViewN/AView Earnings Details
11/5/2015Q3 2015($0.03)ViewN/AView Earnings Details
8/6/2015Q215($0.02)$1.08 millionViewN/AView Earnings Details
5/7/2015Q115($0.02)ViewN/AView Earnings Details
11/6/2014Q3 2014($0.02)ViewN/AView Earnings Details
5/8/2014Q1 2014($0.03)ViewN/AView Earnings Details
3/13/2014Q4 2013($0.02)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.02)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.02)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.03)ViewN/AView Earnings Details
3/14/2013Q4 2012($0.02)ViewN/AView Earnings Details
11/8/2012Q3 2012($0.02)ViewN/AView Earnings Details
8/8/2012Q2 2012($0.03)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.04)($0.04)ViewN/AView Earnings Details
3/14/2012Q4 2011($0.03)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.05)($0.06)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.04)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.05)ViewN/AView Earnings Details
3/31/2008Q4 2007($0.06)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Provectus Biopharmaceuticals (OTCMKTS:PVCT) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Provectus Biopharmaceuticals (OTCMKTS:PVCT)

No dividend announcements for this company have been tracked by

Insider Trades

Provectus Biopharmaceuticals (OTCMKTS PVCT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.50%
Institutional Ownership Percentage: 0.03%
Insider Trades by Quarter for Provectus Biopharmaceuticals (OTCMKTS:PVCT)

Provectus Biopharmaceuticals (OTCMKTS PVCT) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2017John R GlassInsiderBuy200,000$0.05$10,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Provectus Biopharmaceuticals (OTCMKTS PVCT) News Headlines


SEC Filings

Provectus Biopharmaceuticals (OTCMKTS:PVCT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Financials are not available for this stock.


Provectus Biopharmaceuticals (OTCMKTS PVCT) Stock Chart for Saturday, January, 20, 2018

Loading chart…

This page was last updated on 1/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.